HTA - OHE - Page 24

Office of Health Economics

Leading intellectual authority on global health economics

Search publications, topics, authors and more

Newsletter SignupSubscribe

News & Insights

News
Events
Insights
Bulletin

News
Events
Insights
Bulletin

News & Insights

News
Events
Insights
Bulletin

Newsletter SignupSubscribe

News
Events
Insights
Bulletin

Search publications, topics, authors and more

Research & Publications
News & Insights
Education
Innovation Policy Prize

Events
About Us
OHE Experts
Join OHE
Contact Us

Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:

Antimicrobial Resistance (AMR)
Biosimilars
Cell and Gene Therapies
Chronic Diseases
Combination Therapies
COVID-19 Research
Digital Health
Drug Development/R&D
Emerging Markets
EQ-5D and PROMs
Indication-Based Pricing
Health Care Systems
Health Data and Statistics
Health Technology Assessment
Precision Medicine
Prevention
Real-World Evidence
Sustainability
Use of Medicines
Value-Based Pricing
Vaccine Research

Economics of Innovation
Measuring and Valuing Outcomes
Policy, Organisation and Incentives in Health Systems
Value, Affordability and Decision Making

News & Insights

News
Events
Insights
Bulletin

Education

Education Hub
OHE Graduate School
EVIA Programme

Innovation Policy Prize

The Prize Fund
2024 Prize Fund
2022 Prize Fund

Search publications, topics, authors and more

Latest Research & Publications

Health Data and Statistics
Measuring and Valuing Outcomes

The Trajectory of Dementia in the UK – Making a Difference

Health Technology Assessment…
Value, Affordability, and…

Opportunity Costs of Implementing NICE Decisions in NHS Wales

Health Technology Assessment…
Measuring and Valuing Outcomes
Cancer

The Expanding Value Footprint of Oncology Treatments

Economics of Innovation
Cancer

Real Option Value and Path Dependence in Oncology Innovation

Drug Development/R&D
Economics of Innovation

The Current Drug Development Paradigm: Responding to US and European Demands for Evidence of Comparative Effectiveness and Relative Effectiveness

Biosimilars
Measuring and Valuing Outcomes

What is the Role of HTA for Biosimilars?

Health Technology Assessment…
Value, Affordability, and…

Can the US Afford to Ignore Cost-effectiveness Evidence?

Health Care Systems
Policy, Organisation and…
Economic Evaluation

Contracting for Quality in the NHS

All Publications

Filter by:

Antimicrobial Resistance (AMR)

Biosimilars

Cell and Gene Therapies

Chronic Diseases

Combination Therapies

COVID-19 Research

Digital Health

Drug Development/R&D

Emerging Markets

EQ-5D and PROMs

Indication-Based Pricing

Health Care Systems

Health Data and Statistics

Health Technology Assessment

Precision Medicine

Prevention

Real-World Evidence

Sustainability

Use of Medicines

Value-Based Pricing

Vaccine Research

Economics of Innovation

Measuring and Valuing Outcomes

Policy, Organisation and Incentives in Health Systems

Value, Affordability and Decision Making
News

Events

Insights

Bulletin
Education Hub

OHE Graduate School

EVIA Programme
The Prize Fund

2024 Prize Fund

2022 Prize Fund

Events
About Us
OHE Experts
Join OHE
Contact Us

Newsletter SignupSubscribe

Filter results by

Theme

Select the product option you would like to filter Theme

Economics of Innovation Measuring and Valuing Outcomes Policy, Organisation and Incentives in Health Systems Value, Affordability, and Decision Making

Topic

Select the product option you would like to filter Topic

Antimicrobial Resistance (AMR) Biosimilars Cell and Gene Therapies Chronic Diseases Combination Therapies COVID-19 Research Dementia Digital Health Drug Development/R&D Emerging Markets EQ-5D and PROMs Health Care Systems Health Data and Statistics Health Technology Assessment (HTA) Indication-Based Pricing Innovation Policy Prize OHE Consulting Precision Medicine Prevention Real World Evidence (RWE) Research Sustainability Use of Medicines Vaccines Value-Based Pricing

Tag

Select the product option you would like to filter Tag

Adult Immunisation Alzheimer's Cancer Cardiovascular Disorders Care-givers Caring burden Cervical Cancer Clinical Outcomes Commentary Competition Dermatology Determining Value Drug Shortages Economic Evaluation Egypt Epidemiology and Public Health Epilepsy Gene therapies Generics Greece Haemophilia Health Policy and Regulation Healthcare Delivery Healthcare Expenditure Healthcare Funding Healthcare System Pressure (HCSP) India Infectious Diseases Inflation Reduction Act Injury and Trauma Innovation Israel Market Access Mental Health Pharmaceutical Industry Plant-based Policy Analysis Pricing and Reimbursement Primary Care Quality of Care Quality of Life Rare and Orphan Diseases Research Funding Resource Allocation Saudi Arabia Slovak Republic Societal preferences Supply of Medicine Türkiye Unmet Need Vaccines Value based pricing Webinar

Date 1

Select the product option you would like to filter Date

Date From

Month From

Year From

Date To

Month To

Year To

Author

Select the product option you would like to filter Author

Search authors

Andrew Briggs Thomas Pogge Antonella Cardone Stan Jackson Claudio Jommi Carole Longson Dr Tina Wang Lishani Ramanayake Sukanya Subramaniyan Brittany Darrow

Content Type

Select the product option you would like to filter Content Type

news story insight events podcast bulletin publications

News
February 2019

OHE Response to Public Consultation on NICE Principles

News
February 2019

OHE Lecturing for Professional Training at ICPS

News
January 2019

Generating Preference-based Values for the EQ-5D-Y to Support Its Use in HTA

News
January 2019

Public Preferences for Health Gains and Cures: A Discrete Choice Experiment

News
January 2019

OHE Lunchtime Seminar: What Can NHS Trusts do to Reduce Cancer Waiting Times?

Past Event
January 2019

OHE Lunchtime Seminar: What Can NHS Trusts do to Reduce Cancer Waiting Times?

Policy, Organisation and…
Injury and Trauma

Unrelieved Pain in Palliative Care in England

Health Data and Statistics
Economics of Innovation

Data Governance Arrangements for Real-World Evidence in Japan

Antimicrobial Resistance (AMR)
Value, Affordability, and…
Generics

HTA and Payment Mechanisms for New Drugs to Tackle AMR

News
January 2019

Professor Lotte Steuten Appointed OHE Vice President and Head of Consulting

News
January 2019

Professor Mireia Jofre-Bonet Appointed Vice President and Head of Research

EQ-5D and PROMs
Measuring and Valuing Outcomes
Clinical Outcomes

Valuing EQ-5D-Y Health States Using a Discrete Choice Experiment: Do Adult and Adolescent Preferences Differ?

Health Technology Assessment…
Economics of Innovation
Determining Value

The Case of Risperidone: Assessing the Life-cycle Value of Second-Generation Antipsychotics in Sweden and the UK

Value-Based Pricing
Economics of Innovation
Health Policy and Regulation

Documento de debate sobre la fijación de precios en función de la indicación (IBP) ¿Deben variar los precios de los medicamentos según la indicación?

Indication-Based Pricing
Economics of Innovation
Health Policy and Regulation

Indication-Based Pricing (IBP) Discussion Paper: Should drug prices differ by indication?

Leading intellectual authority on global health economics

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Cookies Policy

An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Twitter

Facebook

Copy

Share on Mastodon

Enter your Mastodon instance URL (optional)

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Enable or Disable Cookies

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Enable or Disable Cookies

Please enable Strictly Necessary Cookies first so that we can save your preferences!

The Trajectory of Dementia in the UK – Making a Difference

Opportunity Costs of Implementing NICE Decisions in NHS Wales

The Expanding Value Footprint of Oncology Treatments

Real Option Value and Path Dependence in Oncology Innovation

The Current Drug Development Paradigm: Responding to US and European Demands for Evidence of Comparative Effectiveness and Relative Effectiveness

What is the Role of HTA for Biosimilars?

Can the US Afford to Ignore Cost-effectiveness Evidence?

Contracting for Quality in the NHS

All Publications

Filter results by

OHE Response to Public Consultation on NICE Principles

OHE Lecturing for Professional Training at ICPS

Generating Preference-based Values for the EQ-5D-Y to Support Its Use in HTA

Public Preferences for Health Gains and Cures: A Discrete Choice Experiment

2018 OHE Annual Report to the Charity Commission

OHE Lunchtime Seminar: What Can NHS Trusts do to Reduce Cancer Waiting Times?

OHE Lunchtime Seminar: What Can NHS Trusts do to Reduce Cancer Waiting Times?

Unrelieved Pain in Palliative Care in England

Data Governance Arrangements for Real-World Evidence in Japan

HTA and Payment Mechanisms for New Drugs to Tackle AMR

Professor Lotte Steuten Appointed OHE Vice President and Head of Consulting

Professor Mireia Jofre-Bonet Appointed Vice President and Head of Research

Valuing EQ-5D-Y Health States Using a Discrete Choice Experiment: Do Adult and Adolescent Preferences Differ?

The Case of Risperidone: Assessing the Life-cycle Value of Second-Generation Antipsychotics in Sweden and the UK

Documento de debate sobre la fijación de precios en función de la indicación (IBP) ¿Deben variar los precios de los medicamentos según la indicación?

Indication-Based Pricing (IBP) Discussion Paper: Should drug prices differ by indication?